THANK YOU FOR SUBSCRIBING
The biotech hubs established in various regions of APAC enrich the pharma industry with breakthrough innovations in the biotechnology domain.
FREMONT, CA: Asia-Pacific, one of the progressive regions in the market for pharmaceuticals, is shifting its focus from predominantly producing generics to thriving innovative technologies in the biotech sector. Likewise, the life sciences industry is also witnessing accelerated growth via increased R&D activity, a flow of mergers and acquisitions, an increased population, and the escalating market demand in ageing societies. As a result, biotech hubs have begun to develop as the frontiers of innovative healthcare and sustainability. These breakthrough innovations are likely to propel the biotech market forward at a compound annual growth rate of 16.8 per cent by 2028.
Growing startup ecosystems in Singapore encourage research and development, manufacturing, and commercial operations in the biotech sector. Moreover, the increased government support via policies and public investments is contributing to the nation’s turnover on a huge scale. In due course, the biotech industry is rising as one of the pillars of the country’s economic balance and accounts for nearly five per cent of the gross domestic rate. Popular pharma companies are beginning to shift their intense focus on Singapore owing to its pro-business environment, talented workforce, and infrastructure. Similarly, four of the top ten biotech drugs with the highest global revenue have established nearly 25 R&D centres in the country to support their manufacturing status.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
In addition to the increasing shift of global companies towards the nation, Singapore is making efforts to establish biotech communities on its own. Research states that 350+ companies, ranging from startups to enterprises, have already been established in the country, with their scope rising in recent times. Biotech companies are accelerating across various therapeutic areas and modalities on account of established universities and research institutions located in the realm. Thus, biotech startups are raising millions today and are expected to exceed further in the upcoming period.
Regulation reforms, improving capital markets for foreign investors, bioclusters' formation, and a shift in talent from abroad are driving the biopharma ecosystem of China to generate innovative biotechs. With the molecular entities submitted for clinical trials escalating, the market value of publicly listed innovative biotechs, the Shanghai and Hong Kong Stock Exchanges, and the Science and Technology Innovation Board also accelerates. Similarly, Shanghai, as a prominent biocluster in China and a realm of the Zhangjiang National Innovation Demonstration Zone, hosts 22 investment parks with 1,400 biomedical innovation companies and 330 national R&D institutions.
The total licencing revenue of biomedical companies in Zhangjiang has already surpassed 17.28 billion USD and is anticipated to grow further as a result of innovative platforms and institutions. In addition, new drugs are often introduced for clinical trials, with their availability for usage to increase in the future. Various biotech startups are rising with innovative ideas like nurturing next-generation CAR-T cell therapies, novel vaccines and biologics, mRNA drug platforms, and treatments for metabolic disorders.
Taiwan has begun laying strategies to establish the arena as an R&D hub to champion innovative precision medicine and medical technologies. The industry has a crucial role to play in accelerating the landscape with the aid of proactive government policies and transferable experience in IT. As a result, the biotech sector reached a strike of 23.37 billion USD in the nation’s revenue. Similarly, the Taiwan government’s effective participation in burgeoning the development of innovation clusters pioneers the growth of the National Biotechnology Park, National Taiwan University Hospital Hsinchu Branch, and Southern Taiwan Science Park Smart Biotech Medical Cluster.
The biotech sector, in its peak development in New Zealand, encompasses vast sources besides human healthcare, accounting for 52 per cent on average. Meanwhile, the rest sources of the domain ensure animal health and productivity, marine and agriculture biotechs, and companies focused on rendering renewable and ecosystem support. Sustainability and climate compatibility are reaching their zenith in the arena via the profound exploitation of biotechnology resources. The nation’s wealth hugely relies on animal sciences, marine, horticulture, and biomedical industries, and thus opens wide opportunities in processing bioremediation, biorefinery, plant breeding solutions, and animal-deriving biological development. Despite the challenges like minimum size, venture capital industry, developing infrastructure, and a lack of overseas promotion, New Zealand is reaching great heights in biotechnology innovations with a compound annual growth rate of 7.6–14.5 per cent.
Melbourne, as a realm of biomedical researchers for Australia and its life science companies, is one of the flourishing biotech hubs in the Asia-Pacific region. Hence, the Australian medical research funding, exceeding 40 per cent, is often directed to the city to stimulate effective biotechnology innovations. A startup incubator is likely to be introduced in the upcoming years to accommodate 40 early-stage companies for nurturing their growth. As a primary hub in the industry, it encompasses advanced and innovative manufacturing enterprises, extensive logistic networks, R&D infrastructure, and the inclined support of world-class universities in biomedical research. Almost 250 startups in Melbourne, with a yen desire for ideas, are emerging with cutting-edge solutions as a result of which it remains home to the bionic eye plant, a breakthrough innovation in restoring lost visions.
More in News